Fundraising Fox

Rondo Therapeutics

Founded 2021 · 29 employees on LinkedIn · 1 known investors

Rondo Therapeutics develops immune-engaging bispecific antibodies designed to treat solid tumors with tuned immune-activating arms and tumor-localized activity to reduce side effects. It uses an NGS-based antibody discovery platform to build binding-arm libraries and advance a pipeline of cancer therapeutics for indications such as bladder, ovarian, endometrial, and renal cancers.

BiotechHealthtech

Founders & leadership

Rondo Therapeutics was founded in 2021 by Shelley Force Aldred and Nathan Trinklein.

SFShelley Force Aldred
Shelley Force AldredChief Executive Officer & Co-Founder
NTNathan Trinklein
Nathan TrinkleinChief Scientific Officer & Co-Founder

Investors · 1

SV Health InvestorsBoston · $1M – $20M

In the news

Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs - MedCity Newsmedcitynews.com · Mar 2022Rondo Therapeutics locks in $67m Series Aventurecapitaljournal.com · Mar 2022Vesalius, Rondo Debut to Redefine Treatment Paradigms - BioSpacebiospace.com · Mar 2022Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumorsprnewswire.com · Mar 2022Operations Manager in Fremont at Rondo Therapeutics | Apply now! – StudySmarter – Talentstalents.vaia.com

Frequently asked questions

What does Rondo Therapeutics do?
Rondo Therapeutics develops immune-engaging bispecific antibodies designed to treat solid tumors with tuned immune-activating arms and tumor-localized activity to reduce side effects. It uses an NGS-based antibody discovery platform to build binding-arm libraries and advance a pipeline of cancer therapeutics for indications such as bladder, ovarian, endometrial, and renal cancers.
Who founded Rondo Therapeutics?
Rondo Therapeutics was founded by Shelley Force Aldred, Nathan Trinklein in 2021.
Who are Rondo Therapeutics's investors?
Rondo Therapeutics's investors include SV Health Investors.